Ping Min Selected Research

olverembatinib

1/2022	FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
1/2019	Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ping Min Research Topics

Disease

4	Neoplasms (Cancer) 07/2022 - 09/2013
1	Leukemia 01/2022
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2019
1	Nasopharyngeal Carcinoma 09/2013
1	Neoplasm Metastasis (Metastasis) 09/2013

Drug/Important Bio-Agent (IBA)

2	olverembatinibIBA 01/2022 - 01/2019
1	ErbB Receptors (EGF Receptor)IBA 07/2022
1	trametinibIBA 07/2022
1	Tyrosine Kinase InhibitorsIBA 07/2022
1	Aldehyde DehydrogenaseIBA 07/2022
1	Drug CombinationsIBA 07/2022
1	MitogensIBA 07/2022
1	Tetrazolium SaltsIBA 07/2022
1	Carboplatin (JM8)FDA LinkGeneric 07/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2022
1	osimertinibIBA 07/2022
1	LisaftoclaxIBA 01/2022
1	STAT5 Transcription FactorIBA 01/2022
1	ponatinibIBA 01/2019
1	Imatinib Mesylate (Gleevec)FDA Link 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019

Therapy/Procedure

3	Therapeutics 07/2022 - 09/2013
1	Radiotherapy 09/2013
1	Drug Therapy (Chemotherapy) 09/2013